2. Search Result
Search Result
Results for "

B0180

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Inhibitory Antibodies

4

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0180
    Imiquimod
    Maximum Cited Publications
    58 Publications Verification

    R 837

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod
  • HY-B0180A
    Imiquimod hydrochloride
    Maximum Cited Publications
    58 Publications Verification

    R 837 hydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Neurological Disease Inflammation/Immunology Cancer
    Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod hydrochloride
  • HY-B0180B
    Imiquimod maleate
    Maximum Cited Publications
    58 Publications Verification

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Neurological Disease Inflammation/Immunology Cancer
    Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod maleate
  • HY-B0180R
    Imiquimod (Standard)

    R 837 (Standard)

    		 Reference Standards Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod (Standard)
  • HY-B0180BR
    Imiquimod maleate (Standard)

    		Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Reference Standards Infection Inflammation/Immunology Cancer
    Imiquimod (maleate) (Standard) is the analytical standard of Imiquimod (maleate). This product is intended for research and analytical applications. Imiquimod maleate (R 837 maleate), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod maleate exhibits antiviral and antitumor effects in vivo. Imiquimod maleate can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod maleate (Standard)
  • HY-B0180AR
    Imiquimod hydrochloride (Standard)

    R 837 hydrochloride (Standard)

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Reference Standards Infection Inflammation/Immunology Cancer
    Imiquimod (hydrochloride) (Standard) is the analytical standard of Imiquimod (hydrochloride). This product is intended for research and analytical applications. Imiquimod hydrochloride (R 837 hydrochloride), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod hydrochloride exhibits antiviral and antitumor effects in vivo. Imiquimod hydrochloride can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod hydrochloride (Standard)
  • HY-B0180S1
    Imiquimod-d9

    R 837-d9

    		 Isotope-Labeled Compounds Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod-d9 is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod-d9
  • HY-B0180S
    Imiquimod-d6

    R 837-d6

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod-d6 is the deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod-d6
  • HY-B0180C
    Imiquimod dihydrochloride

    R 837 dihydrochloride

    		 Toll-like Receptor (TLR) Autophagy SARS-CoV HSV Infection Inflammation/Immunology Cancer
    Imiquimod (R 837) dihydrochloride, an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod dihydrochloride
  • HY-B0180S2
    Imiquimod-d7

    R 837-d7

    		 Isotope-Labeled Compounds Toll-like Receptor (TLR) Autophagy HSV SARS-CoV Infection Inflammation/Immunology Cancer
    Imiquimod-d7 (R 837-d7) is deuterium labeled Imiquimod. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19 .
    Imiquimod-d7
  • HY-116330A
    Hyperforin dicyclohexylammonium salt
    3 Publications Verification

    Hyperforin DCHA

    		 TRP Channel Calcium Channel Neurological Disease Cancer
    Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin dicyclohexylammonium salt
  • HY-116330
    Hyperforin

    		Calcium Channel TRP Channel Neurological Disease Inflammation/Immunology
    Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin
  • HY-Y1809
    1-Hydroxyoctadecane

    Stearyl alcohol

    		 Environmental Pollutants Biochemical Assay Reagents Inflammation/Immunology
    1-Hydroxyoctadecane (Stearyl alcohol) is a long-chain fatty alcohol and excipient. 1-Hydroxyoctadecane forms a closed oil film, thereby reducing transepidermal water loss (TEWL) and promoting skin moisturization. 1-Hydroxyoctadecane improves Imiquimod (HY-B0180)-induced psoriatic skin inflammation in mice .
    1-Hydroxyoctadecane
  • HY-156466
    QL-1200186

    		STAT Interleukin Related IFNAR Inflammation/Immunology
    QL-1200186 is a selective, orally active, allosteric inhibitor targeting the tyrosine kinase TYK2 pseudokinase domain JH2 (IC50=0.06 nM, TYK2 JH2), with 164-fold selectivity over TYK1 JH2 (IC50=9.85 nM，TYK1 JH2). QL-1200186 first stabilizes the TYK2 JH2 conformation, inhibits the activity of the JH1 catalytic domain, and blocks the IFNα, IL-12/IL-23-mediated JAK-STAT signaling pathway. QL-1200186 can inhibit the production of Th1/Th17 cell-related cytokines (such as IFNγ, IL-23), reduce immune cell activation, and has no significant effect on JAK1/2/3 kinase activity. QL-1200186 can significantly improve skin inflammation in the Imiquimod (HY-B0180)-induced psoriasis mouse model and reduce the Psoriasis Area and Severity Index (PASI) score. QL-1200186 can be used in the study of autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE) .
    QL-1200186
  • HY-100365
    Remetinostat
    1 Publications Verification

    SHP-141

    		 HDAC Inflammation/Immunology Cancer
    Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180)-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma .
    Remetinostat
  • HY-169853
    M351-0056

    		VISTA Inflammation/Immunology
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models .
    M351-0056
  • HY-162150
    Azalamellarin N
    2 Publications Verification

    AZL-N

    		 Pyroptosis Inflammation/Immunology
    Azalamellarin N is an inhibitor of pyroptosis and has different inhibitory effects on different pyroptosis inducers. Azalamellarin N inhibits pyroptosis by targeting molecules that act upstream of NLRP3 inflammasome activation, rather than directly targeting components of the NLRP3 inflammasome. Inhibitory potency against different pyroptosis inducers: Nigericin (HY-127019) > R837 (HY-B0180) .
    Azalamellarin N
  • HY-175022
    PROTAC IRAK4 degrader-13

    		PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related Inflammation/Immunology
    PROTAC IRAK4 degrader-13 (Degrader 1) is a selective IRAK4 PROTAC degrader with DC50s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker
    PROTAC IRAK4 degrader-13
  • HY-120225
    NJK14047

    		p38 MAPK Inflammation/Immunology
    NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice .
    NJK14047
  • HY-136527
    BMS-986251

    		ROR Interleukin Related Inflammation/Immunology
    BMS-986251 is an orally active and selective RORγt inverse agonist with an EC50 of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC50 of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .
    BMS-986251
  • HY-160097
    AXC-666

    		ADC Payload Drug Derivative Inflammation/Immunology Cancer
    AXC-666, an immune agonist, is a Imiquimod (HY-B0180) derivative .
    AXC-666
  • HY-163176
    WB518

    		STAT Inflammation/Immunology
    WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17 .
    WB518
  • HY-131040
    NLRP3-IN-NBC6

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-NBC6 is a potent, selective NLRP3 inflammasome inhibitor (IC50= 574 nM) that acts independently of Ca 2+. NLRP3-IN-NBC6 inhibits Nigericin (HY-127019)-induced inflammasome activation in THP-1 cells and Imiquimod (HY-B0180)-induced IL-1β release from LPS-primed bone marrow-derived macrophages (BMDMs) .
    NLRP3-IN-NBC6
  • HY-168971
    Paeoniflorin-6′-O-benzene sulfonate

    CP-25

    		 IFNAR STAT TNF Receptor Interleukin Related CXCR JAK G Protein-coupled Receptor Kinase (GRK) Inflammation/Immunology
    Paeoniflorin-6′-O-benzene sulfonate (CP-25) is the inhibitor for G protein-coupled receptor kinase 2 (GRK2) that inhibits the translocation of GRK2 to the cell membrane, inhibits JAK1/STAT3 signaling pathway. Paeoniflorin-6′-O-benzene sulfonate inhibits IL-17A/CXCL2-induced proliferation of HaCaT. Paeoniflorin-6′-O-benzene sulfonate reduces the levels of inflammatory factors and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3 and CXCL9, alleviates Imiquimod (HY-B0180)-induced psoriasis in mouse model .
    Paeoniflorin-6′-O-benzene sulfonate
  • HY-155548
    RORγt inverse agonist 31

    		ROR Inflammation/Immunology
    RORγt inverse agonist 31 (14g) is a potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist, with an IC50 of 0.428 μM. RORγt inverse agonist 31 can alleviate the severity of Imiquimod (HY-B0180)-induced psoriasis in mice .
    RORγt inverse agonist 31
  • HY-168212
    PDE4-IN-22

    		Phosphodiesterase (PDE) TNF Receptor Interleukin Related Inflammation/Immunology
    PDE4-IN-22 (Compound 2e) is a PDE4 inhibitor with an IC50 value of 2.4 nM. PDE4-IN-22 exhibits anti-inflammatory activity and demonstrates significant anti-psoriatic effects in an Imiquimod (HY-B0180)-induced psoriasis mouse model .
    PDE4-IN-22
  • HY-169290
    JAK/HDAC-IN-4

    		JAK HDAC Inflammation/Immunology
    JAK/HDAC-IN-4 (compound 11 i) is a JAK/HDAC inhibitor with the IC50 values of 0.49 nM and 12 nM for JAK2 and HDAC6, respectively. JAK/HDAC-IN-4 inhibits the cell proliferation and the production of nitric oxide. JAK/HDAC-IN-4 ameliorates psoriasis-like skin lesions in an Imiquimod (HY-B0180)-induced murine model with low toxicity .
    JAK/HDAC-IN-4
  • HY-169007
    STAT3-IN-34

    		STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .
    STAT3-IN-34
  • HY-155243
    12R-LOX-IN-1

    		DNA/RNA Synthesis Inflammation/Immunology
    12R-LOX-IN-1 (Compound 4a) is a 12R-LOX inhibitor (IC50: 28.25 μM). 12R-LOX-IN-1 inhibits the hyper-proliferative state and colony forming potential of Imiquimod (HY-B0180)-induced psoriatic keratinocytes. 12R-LOX-IN-1 inhibits reactive oxygen species, Ki67, IL-17A, TNF-α and IL-6 production. 12R-LOX-IN-1 can be used for antipsoriatic research .
    12R-LOX-IN-1
  • HY-P991595
    HB-0017

    		Interleukin Related Inflammation/Immunology
    HB-0017 is a humanized IgG1κ monoclonal antibody inhibitor, targeting IL-17A. HB-0017 inhibits the IL-6 secretion induced by IL-17A with an IC50 of 2.09 nM. HB-0017 significantly decreases ear thickness in Imiquimod (HY-B0180)-induced psoriasis-like mice model and alleviates inflammations in IL-17A-induced arthritis and air pouch mice model. The isotype control for the HB-0017 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001) .
    HB-0017
  • HY-116330AR
    Hyperforin dicyclohexylammonium salt (Standard)

    Hyperforin DCHA (Standard)

    		 Reference Standards TRP Channel Calcium Channel Neurological Disease
    Hyperforin dicyclohexylammonium salt (Standard) is the analytical standard of Hyperforin dicyclohexylammonium salt. This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca 2+ levels by activating Ca 2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .
    Hyperforin dicyclohexylammonium salt (Standard)
  • HY-175782
    SMU-R39

    		Toll-like Receptor (TLR) NF-κB p38 MAPK Inflammation/Immunology
    SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 μM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis .
    SMU-R39
  • HY-100365R
    Remetinostat (Standard)

    SHP-141 (Standard)

    		 HDAC Reference Standards Inflammation/Immunology Cancer
    Remetinostat (Standard) is the analytical standard of Remetinostat (HY-100365). This product is intended for research and analytical applications. Remetinostat (SHP-141) is a hydroxamic acid-based histone deacetylase (HDAC) inhibitor. Remetinostat alleviates Imiquimod (HY-B0180)-induced psoriatic dermatitis. Remetinostat can be used for study of cutaneous T-cell lymphoma .
    Remetinostat (Standard)
  • HY-W744192
    2-Hydroxy Imiquimod

    R-842

    		 Drug Metabolite IFNAR TNF Receptor Interleukin Related Infection Inflammation/Immunology Cancer
    2-Hydroxy Imiquimod (R-842), a hydroxylated metabolite of Imiquimod (HY-B0180), is an immunomodulating agent. 2-Hydroxy Imiquimod can induce IFN-α, TNF-α, IL-1, IL-6 and IL-8 in human blood cells. 2-Hydroxy Imiquimod exhibits antivirus and antitumor activities. 2-Hydroxy Imiquimod can be used for the researches of cancer, infection and immunology .
    2-Hydroxy Imiquimod
  • HY-181796
    TLR7 antagonist-1

    		Toll-like Receptor (TLR) Interleukin Related Inflammation/Immunology
    TLR7 antagonist-1 (Compound 44#) is an orally active, selective TLR7 antagonist with an IC50 value of 0.3 nM against TLR7. TLR7 antagonist-1 selectively binds to TLR7, inhibits its activation, and downregulates the c-Rel signaling pathway. TLR7 antagonist-1 downregulates the mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α. TLR7 antagonist-1 alleviates Imiquimod (HY-B0180)-induced psoriasis-like skin lesions. TLR7 antagonist-1 is applicable to research related to psoriasis .
    TLR7 antagonist-1
  • HY-183326
    Isosorbide di-(methyl fumarate)

    IDMF

    		 Keap1-Nrf2 Inflammation/Immunology
    Isosorbide di-(methyl fumarate) (IDMF), topical DMF (HY-17363) derivative, is an NRF2/ARE pathway activator. Isosorbide di-(methyl fumarate) downregulates ANCR targets, modulates epithelial differentiation, represses proinflammatory cytokine genes, IL-17A- and TNF-induced keratinocyte genes, psoriatic skin lesion-specific genes, and immune response genes. Isosorbide di-(methyl fumarate) stimulates oxidative stress response gene transcription, reduces erythema and scaling in Imiquimod (HY-B0180)-induced psoriasiform lesions. Isosorbide di-(methyl fumarate) exhibits no genotoxicity or radiation sensitivity in skin fibroblasts, is nonirritating and nonsensitizing in rodent models. Isosorbide di-(methyl fumarate) can be used for the research of psoriasis vulgaris .
    Isosorbide di-(methyl fumarate)
  • HY-P992384
    IMG-008

    		Interleukin Related Inflammation/Immunology
    IMG-008 is a fully human antagonistic antibody targeting IL-36R, acting as a high-affinity IL-36R inhibitor (Kd = 6.23 pM). IMG-008 competitively blocks the pro-inflammatory signaling pathway mediated by human IL-36R, inhibiting receptor activation and the production of inflammatory cytokines. IMG-008 suppresses Imiquimod (HY-B0180)-induced skin inflammation in humanized mice, and Fc modification increases its serum exposure and prolongs its half-life. IMG-008 can be used in studies related to IL-36R-mediated inflammatory diseases such as psoriasis .
    IMG-008

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: